INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 08 (2025)
290
THE ROLE OF THE SKIN MICROBIOME IN ATOPIC DERMATITIS: NEW
THERAPEUTIC PERSPECTIVES
Abdujabborov Tokhirjon Kurbanovich,
Department of Dermatovenereology,
Andijan State Medical Institute,
Uzbekistan, Andijan
Abstract:
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease
characterized by intense pruritus and eczematous lesions. Its pathogenesis is increasingly linked
to a profound dysbiosis of the skin microbiome, notably the overabundance of Staphylococcus
aureus. Objective: This review synthesizes the current understanding of the skin microbiome's
role in AD pathogenesis and critically evaluates emerging microbiome-targeted therapeutic
strategies. Main Body: The review highlights that the AD skin microenvironment is
characterized by a significant reduction in microbial diversity and the pathogenic dominance of
S. aureus, which contributes to barrier dysfunction and inflammation. Consequently, therapeutic
strategies aimed at restoring eubiosis—including the use of probiotics, prebiotics, and skin
microbiota transplantation—are emerging as promising approaches to disease management.
Conclusion: Targeting the skin microbiome represents a paradigm shift in dermatology,
offering a novel and promising frontier for developing more effective, personalized, and long-
lasting treatments for atopic dermatitis.
Keywords:
atopic dermatitis, skin microbiome, Staphylococcus aureus, dysbiosis, therapeutic
strategies, probiotics.
Introduction
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense pruritus
(itching), eczematous lesions, and significant skin barrier dysfunction. It is one of the most
common dermatological disorders, affecting up to 20% of children and 3-5% of adults globally,
and it substantially impairs the quality of life for patients and their families. The
pathophysiology of AD is complex and multifactorial, involving a combination of genetic
predisposition, immune system dysregulation, and environmental factors [1].
The human skin is colonized by a diverse community of microorganisms, collectively known as
the skin microbiome, which plays a crucial role in maintaining cutaneous homeostasis and
educating the immune system. In recent years, compelling evidence has emerged highlighting
the profound impact of microbial dysbiosis—an imbalance in the composition and function of
the skin microbiome—on the development and exacerbation of AD. Healthy skin typically
harbors a balanced ecosystem of diverse bacteria, whereas the skin of AD patients is frequently
characterized by a marked reduction in microbial diversity and a significant overabundance of
Staphylococcus aureus.
S. aureus colonization in AD is not merely a consequence of the disease but is an active
contributor to its pathology. This bacterium exacerbates skin inflammation through the
secretion of toxins and superantigens, disrupts the skin barrier, and triggers a pathological
immune response, creating a vicious cycle of inflammation and infection. Consequently,
understanding the intricate interplay between the host and the skin microbiome is paramount for
developing more effective and targeted therapeutic strategies [2].
Despite advancements in treatment, current therapies for AD, such as topical corticosteroids
and calcineurin inhibitors, primarily focus on suppressing the immune response and often have
limitations, including potential side effects and high relapse rates upon cessation. Therefore,
there is a critical need for novel therapeutic approaches that address the underlying microbial
INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 08 (2025)
291
imbalance. This review aims to summarize the current understanding of the skin microbiome's
role in the pathogenesis of AD and to explore emerging microbiome-targeted therapeutic
perspectives, including the use of probiotics, prebiotics, and bacteriotherapy, that hold promise
for the future management of this challenging disease.
The skin microbiome: From homeostasis to ad pathogenesis
The microbiome of healthy skin: A state of eubiosis - in a state of health, the skin is colonized
by a diverse and stable microbial community that exists in a symbiotic relationship with the
host. This state, known as eubiosis, is crucial for maintaining the integrity of the skin barrier
and modulating local immune responses. The composition of this microbiome varies depending
on the skin site (e.g., oily, moist, or dry areas) but is generally dominated by commensal
bacteria such as Cutibacterium acnes, coagulase-negative staphylococci (e.g., Staphylococcus
epidermidis), and various species of Corynebacterium. These commensals play a protective role
by competing with potential pathogens for nutrients and space, and by producing antimicrobial
peptides (AMPs) that inhibit the growth of harmful microorganisms. For instance, S.
epidermidis has been shown to produce AMPs that selectively inhibit S. aureus colonization [5].
The dysbiotic shift in atopic dermatitis - The hallmark of the skin microbiome in AD is a
profound state of dysbiosis, most notably characterized by a dramatic loss of microbial diversity
and the subsequent dominance of Staphylococcus aureus. During disease flares, S. aureus can
constitute over 90% of the total skin microbiome in affected areas, whereas it is found in much
lower abundance on the skin of healthy individuals. This reduction in diversity is not limited to
lesional (affected) skin; even non-lesional skin of AD patients often shows a subclinical
dysbiotic signature, suggesting that this microbial imbalance precedes and contributes to the
clinical manifestation of flares.
The pathogenic role of staphylococcus aureus in AD - the overwhelming presence of S. aureus
is a key driver of AD pathology. Its virulence factors actively contribute to the disease's vicious
cycle. S. aureus secretes a range of exotoxins, including superantigens like Staphylococcal
enterotoxin B (SEB), which trigger a massive, non-specific T-cell activation and subsequent
release of pro-inflammatory cytokines, thereby amplifying the inflammatory response.
Furthermore, S. aureus can form biofilms, which are structured communities of bacteria
encased in a protective matrix. These biofilms enhance bacterial adherence to the skin, provide
resistance to host immune defenses and antimicrobial treatments, and further impair skin barrier
function. This sustained microbial assault perpetuates barrier damage and chronic inflammation,
which are central features of AD.
Emerging microbiome-targeted therapeutic perspectives
The growing understanding of the skin microbiome's role in AD has paved the way for novel
therapeutic strategies aimed at correcting dysbiosis. These approaches move beyond traditional
immunosuppression to restore a healthy microbial ecosystem.
Probiotics, prebiotics, and postbiotics - Modulating the microbiome through beneficial bacteria
and their substrates is a highly promising avenue.
Probiotics: These are live microorganisms that, when administered in adequate amounts, confer
a health benefit. In the context of AD, both oral and topical probiotics are being investigated.
Oral probiotics, such as certain strains of Lactobacillus and Bifidobacterium, are thought to
exert their effects by modulating the systemic immune system via the gut-skin axis. Topical
probiotics, on the other hand, aim to directly reintroduce beneficial bacteria to the skin to
compete with S. aureus and improve barrier function. For example, strains of Roseomonas
mucosa and Staphylococcus epidermidis have shown promise in clinical trials.
INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 08 (2025)
292
Prebiotics: These are substrates that are selectively utilized by host microorganisms, conferring
a health benefit. Topically applied prebiotics, such as certain oligosaccharides, can promote the
growth of beneficial commensal bacteria over pathogens like S. aureus.
Postbiotics: This refers to the application of inanimate microorganisms or their components,
such as lysates or metabolites. These can directly modulate skin immunity and barrier function
without the challenges of keeping bacteria alive in a formulation. Lysates of bacteria like
Vitreoscilla filiformis have been incorporated into emollients and shown to reduce AD severity.
Bacteriotherapy skin microbiota transplantation - a more direct approach to restoring a healthy
microbiome is bacteriotherapy, also known as skin microbiota transplantation (SMT). This
involves the transfer of the complete microbial community from a healthy donor to the skin of
an AD patient. The goal is to re-establish a diverse and stable ecosystem. Early-phase clinical
trials have demonstrated that topically applying a solution containing commensal bacteria from
a healthy donor can significantly reduce S. aureus colonization and improve AD symptoms,
with effects lasting for several months after treatment. While promising, this approach requires
further research to optimize donor screening, application methods, and long-term safety.
Phage therapy - bacteriophage (phage) therapy is an innovative strategy that uses viruses to
specifically target and kill bacteria. Given the central role of S. aureus in AD, phages that
exclusively infect and lyse this bacterium are being explored as a highly targeted treatment.
This approach has the advantage of eliminating the pathogen without harming the beneficial
commensal bacteria, thereby preserving microbial diversity. Preclinical studies and early case
reports have shown the potential of phage therapy to reduce S. aureus load on the skin, but
larger clinical trials are needed to confirm its efficacy and safety in AD patients.
Discussion
The paradigm for understanding and treating atopic dermatitis is undergoing a significant shift,
moving from a purely immune-centric view to a more holistic, ecosystem-based approach that
places the skin microbiome at the center of its pathogenesis. This review has synthesized the
evidence demonstrating that the dysbiotic state, particularly the proliferation of S. aureus, is a
critical driver of AD. The emerging therapeutic strategies—ranging from probiotics to skin
microbiota transplantation and phage therapy—represent a logical and exciting evolution in
dermatological care. They offer the potential for more targeted, effective, and safer long-term
management of AD by addressing a root cause of the disease rather than merely suppressing its
symptoms.
However, the translation of these promising concepts into standard clinical practice faces
several challenges. First, the definition of a "healthy" skin microbiome is not universal and can
vary significantly between individuals. Second, the efficacy of probiotic and prebiotic therapies
can be highly strain-specific and dependent on the formulation and delivery method. For
bacteriotherapy, key questions regarding optimal donor selection, long-term engraftment of the
transplanted microbiome, and safety remain to be fully addressed.
Future research should focus on several key areas. Large-scale, randomized controlled trials are
essential to validate the efficacy and safety of these novel therapies. Longitudinal studies that
track the skin microbiome of AD patients over time will provide deeper insights into the
dynamics of dysbiosis and treatment response. Furthermore, developing personalized treatment
strategies based on an individual's specific microbial signature ("personalized microbiome
medicine") could represent the ultimate goal in AD management. Combining microbiome-
targeted therapies with traditional treatments may also offer synergistic benefits.
Conclusion
In conclusion, the skin microbiome plays a pivotal and undeniable role in the pathogenesis of
atopic dermatitis. The dysbiotic dominance of S. aureus perpetuates a cycle of barrier
INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 08 (2025)
293
dysfunction and inflammation that is central to the disease. Microbiome-targeted therapies are
no longer a futuristic concept but an active and rapidly advancing field of research that holds
immense promise to revolutionize AD management. By aiming to restore microbial balance,
these novel strategies offer a path towards more durable disease control and an improved
quality of life for the millions of patients affected by this chronic condition.
References
1.
Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab.
2015;66(suppl 1):8-16.
2.
Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in
the skin microbiome associated with disease flares and treatment in children with atopic
dermatitis. Genome Res. 2012 May;22(5):850-9.
3.
Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, et al. Antimicrobials from
human skin commensal bacteria protect against Staphylococcus aureus and are deficient in
atopic dermatitis. Sci Transl Med. 2017 Feb 22;9(378):eaah4680.
4.
Myles IA, Earland K, Anderson ED, Moore IN, Kieh MD, Williams KW, et al. First-in-
human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis. JCI
Insight. 2018 May 3;3(9):e120608.
5.
Begishevich, Pakirdinov Adaham, and Fozilov Feruzjon Abdumuminovich.
"NEUROLOGICAL
COMPLICATIONS
OF
HERPES
ZOSTER
AND
THEIR
MANAGEMENT." Ethiopian International Journal of Multidisciplinary Research 12, no. 03
(2025): 77-81.
6.
Paetzold B, Willis JR, Pereira de Lima J, Knödlseder N, Brüggemann H, Quist SR, et al.
Skin microbiome modulation by autologous fecal microbiota transplantation in patients with
atopic dermatitis. Nat Med. 2021 Apr;27(4):644-650.
